Description
Nanomedicines for Breast Cancer Theranostics addresses the translational aspects and clinical perspectives of breast cancer nanomedicine from a multidisciplinary perspective. The book summarizes research efforts at the preclinical and clinical stage of nanostructures and nanomedicine for dealing with the important challenge of nanomedicine translation in breast cancer theranostics. This book is an important resource for those working in both academia and industry, focusing on hot topics in biomaterials, biomedical engineering, drug delivery and oncology.- Shows how the discovery of new nanomedicines is leading directly to an increase in the early-stage diagnosis of breast cancer- Includes coverage of breast cancer nanomedicine standardization and characterization, highlighting newly developed treatments, diagnostics and treatment monitoring tools- Explains why the design of nanobiomaterials make them effective drug carriers when treating breast cancer
Table of Contents
1. Nanomedicine: next generation modality of breast cancer therapeutics2. Physical and Chemical properties of nanostructures3. Biological Perspectives of Hybrid nanostructures4. Novel hybrid nanostructures in breast cancer nanomedicine5. Synergy between nanoparticles and breast cancer theranostics6. Remotely stimulated Nano medicine for breast cancer therapy7. Functional Nanostructures for drug resistant breast cancer theranostics8. Nanomedicine for early diagnosis of breast cancer9. Nanomedicine strategies for chemoresistant breast cancer theranostics10. Cellular Interaction and Toxicity of Nanostructures11. Nano-pharmacokinetics, pharmacodynamics (PK/PD) and clinical relationship12. A New Approach for Cancer Treatment: from Specific Induction of Breast Cancer to Innovative Gold-Nanoparticle Mediated Thermal Therapies13. Development in efficacy assessment in relevant oncology models for breast cancer nanomedicine14. Consensus protocols for animal experimentation and nanomedicine trials at clinical stage in breast cancer15. Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines16. Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine
